Observational studyBMC cancer2025
Venous thromboembolism risk in newly diagnosed lymphoma patients: a real-world prospective observational study from Vietnam National Cancer Hospital.
Observational study in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predictors and Risk Assessment Models for Venous Thromboembolism in Patients Diagnosed with Lymphoma: A Systematic Review.Current oncology (Toronto, Ont.) · 2026Pooled it
- Risk Assessment for Venous Thrombosis in Lymphoma and Emerging Biomarkers.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenous thromboembolism (VTE) is a significant cause of morbidity and mortality in cancer patients, with lymphoma being recognized as a high-risk malignancy. Real-world evidence from Southeast Asia, particularly Vietnam, remains limited. This study aimed to assess the incidence and risk factors for VTE among newly diagnosed lymphoma patients receiving systemic therapy in a real-world clinical setting.
methodsWe conducted a prospective descriptive study of 157 newly diagnosed Hodgkin and non-Hodgkin lymphoma patients treated at Vietnam National Cancer Hospital from January 2022 to January 2024. VTE risk was evaluated via the Khorana score at baseline and throughout chemotherapy. Doppler ultrasound and computed tomography were used for VTE screening. Multivariate logistic regression analysis identified independent risk factors for VTE.
resultsThe incidence of VTE in this cohort was 8.3%, and patients were predominantly diagnosed at baseline (7.0%), with only two cases (1.3%) occurring during chemotherapy. The baseline Khorana risk assessment classified 68.2% of patients as low-risk and 7.6% as high-risk, with the proportion of high-risk patients decreasing progressively during treatment. Multivariate analysis revealed elevated pretreatment D-dimer levels (> 500 ng/mL; OR = 0.044, 95% CI: 0.003-0.632, p = 0.022) and cardiovascular comorbidities (OR = 0.036, 95% CI: 0.002-0.545, p = 0.016) as independent predictors of VTE.
conclusionNewly diagnosed lymphoma patients presented an 8.3% incidence of VTE, primarily at initial diagnosis. Elevated D-dimer levels and cardiovascular comorbidities independently predict increased thrombotic risk. The incorporation of routine D-dimer measurements and comprehensive clinical evaluations into standard pretreatment assessments could improve prophylactic strategies and patient outcomes in lymphoma care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.